Survival by BRAF status in stage I, III and IV tumours had overlapping CIs, but cohort numbers were smaller for these groups, and all but stage III tumours showed a trend towards worse outcomes in BRAF-mutated tumours. The gene discussed is BRAF; the disease is neoplasm.